Biomarin Pharmaceutical

Yahoo Finance • 13 days ago

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fur... Full story

Yahoo Finance • 28 days ago

Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More

mezzotint / Shutterstock.com Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of... Full story

Yahoo Finance • last month

Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 21 and set a price target of $90.BioMarin Pharmace... Full story

Yahoo Finance • last month

BioMarin outlines $900M–$935M VOXZOGO 2025 revenue target and plans ROCTAVIAN divestiture amid evolving competitive landscape

Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 MANAGEMENT VIEW * Alexander Hardy, President and CEO, reported "strong results across the business, leading us to raise full year total revenues guidance at the midpoi... Full story

Yahoo Finance • last month

BioMarin seeks to divest hemophilia A gene therapy Roctavian

[BioMarin] hapabapa * BioMarin Pharmaceutical (NASDAQ:BMRN [https://seekingalpha.com/symbol/BMRN]) said it will look to divest Roctavian (valoctocogene roxaparvovec), a one-time gene therapy for hemophilia A to focus more on its core tr... Full story

Yahoo Finance • last month

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercia... Full story

Yahoo Finance • last month

Biomarin Pharmaceutical Q3 25 Earnings Conference Call At 4:30 PM ET

(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on October 27, 2025, to discuss Q3 25 earnings results. To access the live webcast, log on to https://investors.biomarin.com/events-and-presentation... Full story

Yahoo Finance • 2 months ago

Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Tealwood Asset Management Inc. expanded its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN... Full story

Yahoo Finance • 2 months ago

Sum Up The Pieces: MDYV Could Be Worth $94

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation

Value investing remains one of the most enduring investment strategies, focusing on identifying stocks trading below their intrinsic worth. The approach, pioneered by Benjamin Graham and later refined by investors like Warren Buffett, emph... Full story

Yahoo Finance • 3 months ago

Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best cheap strong buy stocks to buy now. Bernstein analyst William Pickering maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 19, assigning the stock a... Full story

Yahoo Finance • 3 months ago

Global Surgical Sutures Market Poised to Reach USD 6.65 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global surgical sutures market, valued at US$4.56 billion in 2024, stood at US$4.84 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culmin... Full story

Yahoo Finance • 4 months ago

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential

Value investing focuses on finding stocks priced below their true value while showing good financial strength, earnings potential, and room for expansion. The "Decent Value" screen selects companies with a valuation score above 7, meaning... Full story

Yahoo Finance • 4 months ago

Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top most undervalued biotech stocks to buy now. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 6, keepi... Full story

Yahoo Finance • 4 months ago

BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald

Investing.com - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), currently trading at $63.50 and rated "Great" by InvestingPro’s comprehensive health score system, received a reiterated Overweight rating and $90.00 price target from Cantor Fitz... Full story

Yahoo Finance • 4 months ago

BioMarin stock rating reiterated at Buy by Stifel on strong Q2 results

Investing.com - Stifel has reiterated its Buy rating and $91.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) following the company’s second-quarter financial results that exceeded analyst expectations. According to InvestingP... Full story

Yahoo Finance • 4 months ago

BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333

Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 MANAGEMENT VIEW * Alexander Hardy, President and CEO, reported "strong growth, exciting progress across the pipeline and delivery of our business development strategy.... Full story

Yahoo Finance • 4 months ago

BioMarin shares gain as Q2 earnings smash estimates

Investing.com -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares jumped 4.5% after the biotech company reported second-quarter earnings that significantly exceeded analyst expectations, driven by strong sales of its rare disease treatmen... Full story

Yahoo Finance • 5 months ago

Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money

Key Points The Nasdaq Composite has been on a roller-coaster ride in 2025, with the index enduring a short-lived bear market that's now given way to a new bull market. Although the stock market is historically pricey, pockets of value ca... Full story

Yahoo Finance • 5 months ago

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential.On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc. T... Full story